22 results about "Streptococcus pneumoniae pneumonia" patented technology

The invention belongs to the technical field of biology, and particularly relates to a primer probe composition and a kit for detecting lower respiratory tract infection pathogens. The primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae, and the primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae. The composition is one or more of a composition for detecting staphylococcus aureus, a composition for detecting streptococcus pneumoniae, a composition for detecting escherichia coli, a composition for detecting moraxella catarrhalis, a composition for detecting serratia marcescens, a composition for detecting mycoplasma pneumoniae, a composition for detecting candida albicans or a composition for detecting adenovirus; the RAA-RDB technology has the core advantages of rapidness, high sensitivity, low cost and easy operation, and is especially suitable for multiple pathogen screening and basic medical application.

The present invention provides a Lactiplantibacillus plantarum strain capable of resisting Streptococcus pneumoniae infection in the respiratory tract, with a deposit number of CCTCC NO: M2022359. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has a strong adhesion effect on nasal epithelial cells and can colonize in the nasal cavity; and can significantly inhibit the adhesion effect of Streptococcus pneumoniae, the main pathogenic microorganism of sinusitis, on nasal epithelial cells; it also has an inhibitory effect on the growth of most other pathogenic microorganisms of sinusitis, including β-hemolytic streptococcus, Streptococcus pyogenes, Escherichia coli, Staphylococcus aureus, etc. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has no toxic effect on the body and has good safety. It can be added to drugs for preventing respiratory diseases or improving respiratory symptoms caused by bacterial infections, and has broad application prospects.

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

The present invention relates to the technical field of biologics, and in particular to a method for preparing a Streptococcus pneumoniae capsular polysaccharide. The present invention provides a method for preparing a Streptococcus pneumoniae capsular polysaccharide. The method comprises: using β-propiolactone to treat a Streptococcus pneumoniae fermentation culture, separating and collecting a supernatant, purifying the supernatant, and collecting a capsular polysaccharide. In the present invention, β-propiolactone is used to treat the Streptococcus pneumoniae fermentation culture, thereby reducing residual impurities such as proteins, and achieving relatively high polysaccharide yield; in addition, the β-propiolactone is susceptible to hydrolysis, and the hydrolysate is non-toxic and harmless and has higher safety. The Streptococcus pneumoniae capsular polysaccharide prepared by the method of the present invention have quality control indexes meeting requirements, and can be used for preparing a Streptococcus pneumoniae capsular polysaccharide vaccine and a polysaccharide conjugate vaccine.

The present invention adopts the RPA combined with the LFS technology to establish a rapid and sensitive on-site detection method for Streptococcus pneumoniae. This method designs primers and probes based on the autolysin gene (lytA) of Streptococcus pneumoniae and completes the detection within 30 minutes at 37°C. By detecting 22 clinical isolates of Streptococcus pneumoniae and 20 other common pathogenic bacteria, the specificity of this method was verified. Ten independent experiments were carried out on the sensitivity of the RPA-LFS method, and the lowest detection limit was 3.32 colony forming units (CFU) / reaction. Finally, the established RPA-LFS detection method for Streptococcus pneumoniae was used to detect clinical specimens. Compared with the PCR method, the detection results were accurate and consistent. In summary, this study developed a rapid, sensitive and specific RPA-LFS detection method for Streptococcus pneumoniae, which has good application prospects in primary medical diagnosis in remote and resource-limited areas.

The application discloses a Streptococcus pneumoniae glycoprotein biological combination vaccine and a preparation method and application thereof. The application provides application of a recombinant plasmid with DNA molecule A and a recombinant plasmid with DNA molecule B in preparation of a Streptococcus pneumoniae vaccine; the DNA molecule A has a CPS synthesis related gene cluster of a Streptococcus pneumoniae K5 serotype; the DNA molecule B has a pglL gene and a fusion gene I; the fusion gene I comprises, from upstream to downstream, an NP gene and a gene coding a glycosylation site. In the application, the Streptococcus pneumoniae K5 serotype CPS is transferred to a carrier protein by means of a PglL system, and the obtained glycoprotein has a Streptococcus pneumoniae vaccine function. The application has important application and popularization values for prevention and control of the Streptococcus pneumoniae and treatment of diseases caused by the Streptococcus pneumoniae.

The invention belongs to the field of biological medicines, and particularly relates to a Tibetan medicine composition for inhibiting streptococcus pneumoniae as well as a preparation method and application of the Tibetan medicine composition. The Tibetan medicine composition comprises anemone vitifolia root, dandelion, barberry bark, rumex madaio, astragalus membranaceus and angelica sinensis. The Tibetan medicine composition can significantly inhibit streptococcus pneumoniae, has a significant treatment effect on pneumonia caused by streptococcus pneumoniae, can improve the inflammatory response of a body, and reduces the infiltration and injury effects of streptococcus pneumoniae on lung tissues; and the oral administration LD50 of mice is greater than 5000mg / kg, and the safety is good.

The present invention discloses the application of iron-tetracycline nanozymes in the preparation of drugs for treating bacterial meningitis, and belongs to the field of medical technology. The present invention provides a new theoretical strategy for the treatment of bacterial meningitis by integrating the reactive oxygen species scavenging ability of iron-based nanozymes and the broad-spectrum antibacterial effect of tetracycline. Experimental results show that the scavenging rate of iron-tetracycline nanozymes for DPPH and ABTS free radicals is as high as 80%, and hydroxyl free radicals can be effectively degraded. ELISA results show that iron-tetracycline nanozymes can significantly inhibit the secretion of pro-inflammatory factors by BV2 cells, confirming its potential to alleviate neuroinflammation by regulating ROS levels. In addition, the inhibition rate of iron-tetracycline nanozymes on Streptococcus pneumoniae is concentration-dependent, and has excellent biocompatibility, providing new raw materials and treatment methods for the treatment of bacterial meningitis caused by Streptococcus pneumoniae.

There is currently a high demand for new therapeutic antibiotics with new mechanisms of action. Disclosed are two small molecules, tryglysin A and B, with novel chemical structures and potent antibiotic activity against a narrow spectrum of bacteria. This narrow spectrum of activity indicates the tryglysins could be working through a novel antibiotic mechanism of action. Due to this narrow spectrum, the tryglysins could be used as highly targeted therapeutics to treat or prevent disease without disturbing other important, “beneficial” bacteria within the human microbiome, which is a great improvement over virtually all other clinically used antibiotics that are broad-spectrum. The tryglysins are potent against several streptococcal pathogens, including Streptococcus pneumonia, the leading cause of pneumonia, and Streptococcus mutans, the primary causative agent of tooth decay and gum disease. The tryglycins may allow the development of therapeutics for the treatment and / or prevention of disease caused by these streptococci.

The invention belongs to the technical field of a streptococcus pneumoniae capsular polysaccharide vaccine produced by biological fermentation. According to the escherichia coli probiotic EcN engineering strain provided by the invention, compared with an original strain EcN, genes wecA and waaL are knocked out; meanwhile, plasmid is used for expressing a streptococcus pneumoniae capsular polysaccharide synthesis gene cluster to obtain an EcN engineering strain. Specific antiserum identification of capsular polysaccharide shows that the EcN engineering strain can synthesize streptococcus pneumoniae capsular polysaccharide, not only can synthesize neutral polysaccharide, but also can synthesize negatively-charged acidic polysaccharide. Moreover, compared with streptococcus pneumoniae, the capsular polysaccharide chain synthesized by the EcN engineering strain is longer, higher in yield and high in homogeneity; and sterilization is not needed, so that the method is safe and easy to operate. The method disclosed by the invention can be used for preparing streptococcus pneumoniae polysaccharide vaccines, and also can be used for synthesizing polysaccharide vaccines in intestinal tracts by orally taking escherichia coli probiotic engineering bacteria.

The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.

The invention discloses an alveolar macrophage inhibitory natural product monomer and application thereof, and relates to the technical field of biological medicines. Seven natural product monomers including polyphyllin B, gentisic acid, catalpol, abscisic acid, aescin, ginsenoside and guaiacol are obtained through screening, and the menin / SETD2 interaction can be specifically inhibited. Experiments show that the monomers can inhibit expression of various inflammatory factors such as IL-1alpha, IL-1beta, IL-6 and the like induced by LPS in a dose-dependent manner; animal experiments prove that the monomers can obviously inhibit release of inflammatory factors induced by pathogens such as LPS and streptococcus pneumoniae, and can effectively relieve acute pneumonia and lung injury of mice. The provided natural product monomer is clear in target spot, specific in effect and broad in anti-inflammatory effect spectrum, and has important application prospects in treatment of cell / inflammatory factor storm related diseases caused by abnormal activation of alveolar macrophages.

The invention discloses a compound composition for moistening lung and protecting throat based on turnip and a preparation method thereof. The composition comprises a turnip active component, tremella polysaccharide, modified propolis nanoparticles, fucoidan, a loquat leaf extract and a menthol-cyclodextrin inclusion compound. In the preparation process, firstly, glucosinolate in turnip is efficiently converted into active substances such as sulforaphane through glucosinase; then designing and synthesizing modified propolis nanoparticles to embed propolis flavonoids and phenolic acids, so as to improve the stability and bioavailability of the propolis flavonoids and phenolic acids; finally, all the components are integrated, and the final product is prepared through the processes of gel compounding, spray drying and the like. The raphanin content of the product reaches 9.17 mg / g, the diameters of inhibition zones on staphylococcus aureus and streptococcus pneumoniae reach 17.6 mm and 16.97 mm respectively, the inhibition rate of mouse cough reaches up to 57.14%, and the problems that a traditional product is unstable in active ingredient and single in effect are solved.

The invention provides a yin-nourishing and lung-moistening fermentation composition and a preparation method thereof. The yin-nourishing and lung-moistening composition with efficient bacteriostatic activity is produced on the basis of a stepped fermentation process. The method comprises the following steps: firstly, carrying out first-stage fermentation on radix ophiopogonis and codonopsis pilosula by utilizing plant lactobacillus MG360; after fermenting for 12 hours, supplementing the extracts of the pears, the liquorice and the loquats and the casei paracasei ID001, and carrying out second-stage fermentation. According to the unique stepped fed-batch fermentation process, the antibacterial effect of the plantaricin EF on pneumonia-related pathogenic bacteria, including streptococcus pneumoniae, beta hemolytic streptococcus, pyogenic streptococcus, escherichia coli, staphylococcus aureus and the like, can be remarkably improved. Meanwhile, the expression of related genes pln-E and pln-F is up-regulated. Animal experiments prove that the composition has excellent effects of nourishing yin, moistening the lung, clearing away the lung-heat and resisting inflammation. The traditional medicinal and edible raw materials are combined with the modern microbial fermentation technology, and a new strategy is provided for developing novel functional products capable of nourishing yin, moistening the lung and resisting infection.

The invention discloses application of iron-tetracycline nano-enzyme in preparation of a medicine for treating bacterial meningitis, and belongs to the technical field of medicines. By integrating the active oxygen scavenging capacity of the iron-based nano-enzyme and the broad-spectrum antibacterial effect of tetracycline, a new theoretical strategy is provided for treatment of bacterial meningitis. Experimental results show that the scavenging rate of the iron-tetracycline nano-enzyme on DPPH and ABTS free radicals reaches up to 80%, and hydroxyl free radicals can be effectively degraded. ELISA results show that the iron-tetracycline nano-enzyme can significantly inhibit BV2 cells from secreting proinflammatory factors, and it is proved that the iron-tetracycline nano-enzyme has the potential of relieving neuroinflammation by regulating the ROS level. Besides, the iron-tetracycline nano-enzyme has concentration dependence on the bacteriostasis rate of streptococcus pneumoniae and has excellent biocompatibility, and a new raw material and a new treatment method are provided for treating bacterial meningitis caused by streptococcus pneumoniae.

The present invention discloses a PCR-RFLP identification method for six phase subtypes of the Streptococcus pneumoniae type I methylation modification system, which relates to the field of biotechnology. This PCR-RFLP identification method realizes the identification or auxiliary identification of six phase subtypes of the Streptococcus pneumoniae type I methylation modification system by using primers with nucleotide sequences shown in SEQ ID No: 1 to 4 to perform PCR amplification on a sample containing the Streptococcus pneumoniae genome, and then using AccI, HindIII, and BstN I to digest the PCR amplification product.

FIELD: occupational medicine.SUBSTANCE: used to diagnose immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in the solid phase. Samples of venous blood and smears from the mucous membrane of the pharynx are taken. In the presence of Streptococcus pneumoniae DNA in scrapings from the mucous membrane of the pharynx and with the level of immunoglobulin M in the blood serum≤ 1.7 g / l is used to diagnose immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in the solid phase.EFFECT: method provides the possibility of selecting immunocompromised workers exposed to industrial mixed aerosols for priority vaccination against pneumococcal infection at the stage of periodic medical examination, by determining the level of immunoglobulin M in the blood serum and Streptococcus pneumoniae DNA in swabs from the mucous membrane of the pharynx.1 cl, 1 tbl, 1 ex

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. The immunogenic compositions of the present invention generally comprise glycoconjugates of at least one Streptococcus pneumoniae serotype not found in and / or in. The invention also relates to vaccination of human subjects, in particular infants and elderly people, against Streptococcus pneumoniae infection using said novel immunogenic compositions.

The invention belongs to the field of molecular diagnostic biology, and relates to a primer, a probe, a kit and a detection method for quantitatively detecting streptococcus pneumoniae, the primer comprises an upstream primer for detecting streptococcus pneumoniae, a downstream primer for detecting streptococcus pneumoniae, an internal control gene upstream primer and an internal control gene downstream primer, the probe comprises a streptococcus pneumoniae detection probe and an internal control gene probe; the nucleotide sequence of the upstream primer for detecting the streptococcus pneumoniae is as shown in SEQ ID NO: 1, and the nucleotide sequence of the downstream primer for detecting the streptococcus pneumoniae is as shown in SEQ ID NO: 2; the nucleotide sequence of the upstream primer of the internal control gene is as shown in SEQ ID NO: 3, and the nucleotide sequence of the downstream primer of the internal control gene is as shown in SEQ ID NO: 4; the nucleotide sequence of the streptococcus pneumoniae detection probe is as shown in SEQ ID NO: 5, and the nucleotide sequence of the internal control gene probe is as shown in SEQ ID NO: 6. According to the application, the sensitivity and accuracy of streptococcus pneumoniae detection can be improved; operation is simple and detection efficiency is high.

The invention belongs to the technical field of medicines, and particularly relates to application of a beta-carboline compound ZLWH-67 in preparation of a medicine for treating skin and pneumonia infection. The ZLWH-67 disclosed by the invention has remarkable antibacterial activity on gram-positive bacteria including MRSA and / or enterococcus faecalis and / or staphylococcus epidermidis and / or streptococcus pneumoniae and drug-resistant bacteria of the gram-positive bacteria. The ZLWH-67 has the effects of bactericidal characteristic, low cytotoxicity, low hemolytic toxicity, good in-vivo biological safety and low drug resistance tendency. From a specific mechanism, the ZLWH-67 inhibits biofilm formation and destroys cell walls, the destroy leads to increase of active oxygen in cells, cytoplasmic DNA leakage and DNA synthesis inhibition, and finally, bacterial death is accelerated, so that the application of the ZLWH-67 in skin and pneumonia infection drugs is realized. Especially in the application of preparing medicines for skin and pneumonia infection, the anti-MRSA activity of the ZLWH-67 has important clinical application value.

The present invention relates to the technical field of biological products, in particular to a method for preparing a Streptococcus pneumoniae capsular polysaccharide or a degraded polysaccharide thereof. Said method comprises: sterilizing a fermentation culture of Streptococcus pneumoniae, separating a supernatant; and sequentially performing first ultrafiltration treatment, precipitation treatment and second ultrafiltration treatment on the supernatant, or sequentially performing first ultrafiltration treatment, precipitation treatment, degradation treatment and second ultrafiltration treatment on the supernatant, a precipitant used in the precipitation treatment comprising a calcium salt, and the precipitation treatment being performed under a condition that the pH is 2.4-3.6. The method has the advantages of simple process and short preparation period, thus remarkably reducing the cost in time and materials; in addition, quality control indexes, including impurities such as nucleic acids and proteins and specific groups, of the prepared refined polysaccharide and degraded polysaccharide are superior to standards, so that said polysaccharide and degraded polysaccharide can be used for preparing Streptococcus pneumoniae capsular polysaccharide vaccines or conjugate vaccines.

The invention belongs to the technical field of medical biology, and particularly discloses application of streptococcus pneumoniae peptide chain endonuclease O (PepO) in preparation of a medicine for treating ulcerative colitis. The invention finds that the streptococcus pneumoniae endonuclease O (PepO) regulates the composition of intestinal flora, inhibits the recruitment of macrophages, down-regulates the expression of intestinal proinflammatory factors and enhances the barrier function of the intestinal tract through a TLR2 receptor in vivo, thereby relieving ulcerative colitis.